Burden of Hepatocellular Carcinoma in Asia

  • Fazeli, Zeinab (Student's Research Commitee, Shahid Begeshti University of Medical Sciences) ;
  • Pourhoseingholi, Mohamad Amin (Gastroenterology and Liver Diseases Research Center, Shahid Begeshti University of Medical Sciences) ;
  • Vahedi, Mohsen (Department of Epodemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences) ;
  • Zali, Mohammad Reza (Gastroenterology and Liver Diseases Research Center, Shahid Begeshti University of Medical Sciences)
  • Published : 2012.12.31


Hepatocellular carcinoma (HCC), the sixth most prevalent cancer worldwide, continues to have high prevalence in many countries of Asia. The main challenge is the high prevalence of chronic hepatitis and aflatoxin, for example in China. HBV vaccination should be the major preventive tactic in Asian countries. The burden of HCC is low in Iran because most cases are due to HBV and this infection was less common. Although in Iran, a mass vaccination program started in 1993, its impact on decreasing the burden of HCC due to HBV can only be expected in future decades.


Hepatocellular carcinoma;burden;Asia


  1. Noh DK, Choi KS, Jun JK, et al (2012). Factors associated with attending the national cancer screening program for liver cancer in Korea. Asian Pac J Cancer Prev, 13, 731-6.
  2. Okuda K (1992). Hepatocellular carcinoma: Recent progress. Hepatology, 5, 948-63.
  3. Oshima A, Tsukuma H, Hiyama T, et al (1984). Follow-up study of HBsAg-positive blood donors with special reference to effect of drinking and smoking on development of liver cancer. Int J Cancer, 34, 775-9.
  4. Park JW, Kim CM (2005). Epidemiology of heptocellular carcinoma in Korea. Korean J Hepatol, 11, 303-10.
  5. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
  6. Parkin DM, Whelan SL, Ferlay J, et al (2002). Cancer Incidence in Five Continents IARC Scientific Publications No. 155, vol. VIII. Lyon: IARC Press.
  7. Pourhoseingholi MA, Fazeli Z, Zali MR, Alavian SM (2010). Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev, 11, 859-62.
  8. Qian GS, Ross RK, Yu MC, et al (1994). A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, people's republic of China. Cancer Epidemiol Biomarkers Prev, 3, 3-10.
  9. Siddique I, El-Naga HA, Memon A, et al (2004).CLIP score as a prognostic indicator for Hepatocellular carcinoma: experience with patients in the Middle East. Euro J Gastro Hepatol, 16, 675-80.
  10. Sin HR, Lee CU, Park HJ, et al (1996). Hepatitis B and C virus, for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol, 25, 933-40.
  11. Shamszad M, Farzadgan H (1982). Hepatitis B related cirrhosis and hepatocellular carcinoma in Iran. J Iranian Med Council, 8, 238.
  12. Sun CA,Wu DM, Lin CC, et al (2003). Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol, 157, 674-82.
  13. Taylor-Robinson SD, Foster GR, Arora S, et al (1997). Increase in primary liver cancer in the UK, 1979-1994. Lancet, 350, 1142-3.
  14. Teo EK, Fock KM (2001). Hepatocellular Carcinoma: An Asian Perspective. Dig Dis, 19, 263-8.
  15. Yang GH, Wang JF, Wan X, et al (2005). Quantitative analysis of factors affected mortality trend in Chinese, 2002. Zhonghua Liu Xing Bing Xue Za Zhi, 26, 934-8.
  16. Yoshimi I, Sobue T (2003). Mortality trend of liver cancer in Japan: 1960-2000. Jpn J Clin Oncol, 33, 202-3.
  17. You SL ,Yang HI, Chen CJ (2004). Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Ann Med, 36, 215-24.
  18. Yu MC, Yuan, J-M, Govindarajan S, Ross RK (2000). Epidemiology of hepatocellular carcinoma. Can J Gastroenterol, 14, 703-9.
  19. World Health Organization (2007). Cancer.
  20. Huang JQ, Zheng GF, Lai CL, et al (2011). Risk of liver cancer in patients with hepatitis B or C. Hong Kong Med J, 17, 41-3.
  21. IARC (1987). Monographs, Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs, vol. 1-42, supplement 7. Lyon: IARC Press.
  22. Kao JH, Chen DS (2005). Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int, 25, 696-703.
  23. Kao JH, Tsai SL, Chen PJ, et al (1994). A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. J Hepatol, 21, 244-9.
  24. Kao JH, Chen DS (1999). Hepatocellular carcinoma in Taiwan: progress in the past decade 1988-1997. In: Leong ASY, Liew CT, Lau JWY, Johnson PJ, eds. Hepatocellular Carcinoma: Contemporary Diagnosis, Investigation and Management. London: Arnold, 235-50.
  25. Kim SR, Kudo M, Hino O, et al (2008). Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology, 75, 13-6.
  26. Kumar V, Fausto N, Abbas A (editors) (2003). Robbins & Cotran Pathologic Basis of Disease (7th ed.). Saunders. pp. 914-7.
  27. Koriech O, Al-Kuhaymi R (1994). Profile of cancer in Riyadh armed forces hospital. Ann Saudi Med, 14, 187-94.
  28. Lai EC, Lau WY (2005). The continuing challenge of hepatic cancer in Asia. Surgeon, 3, 210-5.
  29. Law MG, Roberts SK, Dore GJ, Kaldor JM (2000). Primary hepatocellular carcinoma in Australia, 1978-1997: Increasing incidence and mortality. Med J Aust, 173, 403-5.
  30. Liu Y, Chang CC, Marsh GM, Wu F (2012). Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer, 48, 2125-36.
  31. Liu Y, Wu F (2010). Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect, 118, 818-24.
  32. Makimoto K, Higuchi S (1999). Alcohol consumption as a major risk factor for the rise in liver cancer mortality rates in Japanese men. Int J Epidemiol, 28, 30-4.
  33. Matsuda T, Saika K (2012). Trends in liver cancer mortality rates in Japan, USA, UK, France and Korea based on the WHO mortality database. Jpn J Clin Oncol, 42, 360-1.
  34. McGlynn KA, London WT (2005). Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol, 19, 3-23.
  35. McGlynn KA, Tsao L, Hsing AW, et al (2001). International trends and patterns of primary liver cancer. Int J Cancer, 94, 290-6.
  36. Merat S, Malekzadeh R, Rezvan H, Khatibian M (2000). Hepatitis B in Iran. Arch Iran Med, 3, 192-201.
  37. Ming L, Thorgeirsson SS, Gail MH, et al (2002). Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology, 36, 1214-20.
  38. Cai L, Chongsuvivatwong V, Geater A (2008). Changing pattern of premature mortality burden over 6 years of rapid growth of the economy in suburban south-west China: 1998-2003. Public Health, 122, 478-86.
  39. CDC (2003). Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR, 52, 868-9.
  40. Chang MH, Chen CJ, Lai MS, et al (1997). Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med, 336, 1855-9.
  41. Chen JG, Zhang SW (2011). Liver cancer epidemic in China: past, present and future. Semin Cancer Biol, 21, 59-69.
  42. Colombo M, Kuo G, Choo Q, et al (1989). Prevalence of antibodies to hepatitis C virus in Italian patients with Hepatocellular carcinoma. Lancet, 2, 1006-8.
  43. Chen DS (1993). From hepatitis to hepatoma: lessons from type B viral hepatitis. Science, 262, 369-70.
  44. Chen DS (1995). Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp, 25, 27-32.
  45. Chen CH, Chen YY, Chen GH, et al (2004). Hepatitis B virus and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. J Hepatol, 40, 653-9
  46. Chen CJ, Yu MW, Liaw YF (1997). Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol, 12, 294-308.
  47. Chuang SC, La Vecchia C, Boffetta P (2009). Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett, 286, 9-14.
  48. Deuffic S, Poynard T, Buffa L, Valleron AJ (1998). Trends in primary liver cancer. Lancet, 351, 214-5.
  49. Di Bisceglie AM, Lyra AC, Schwartz M, et al (2003). Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol, 98, 2060-3.
  50. Drinking in the United States: main findings from the 1992 National Longitudinal Alcohol Epidemiology Survey (NLAES) (1998). US Alcohol epidemiology Data Reference Manual, Volume 6, First Edition. NIAAA/NIH NIH Publication No. 99-3519.
  51. Fallot G, Neuveut C, Buendia MA (2012). Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol, 2, 467-73.
  52. Gomaa AI, Khan SA, Toledano MB, et al (2008). Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14, 4300-8.
  53. Gwack J, Park SK, Lee EH, et al (2011). Hepatitis B vaccination and liver cancer mortality reduction in Korean children and adolescents. Asian Pac J Cancer Prev, 12, 2205-8.
  54. Hajiani E, Masjedzadeh R, Hasehemi J, et al (2005). Risk factors for hepatocellulr carcinoma in southern Iran. Saudi Med J, 26, 974-7.
  55. Han KH, Ahn SH (2005). How to predict HCC development in patents with chronic B-viral liver disease? Intervirology, 48, 23-8.
  56. Alavian SM, Fallahian F, Lankarani KB (2007). The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis, 16, 403-6.
  57. Anand R (2002). Aflatoxins, in: IARC monograph on the evaluation of carcinogenic risks to humans, vol. 82, in: Some Traditional Herbal Medicines Some Mycotoxins, Naphthalene and Styrene, McGraw-Hill, New York, 171-300.
  58. Bae JM, Jung KW, Won YJ (2002). Estimation of cancer deaths in Korea for the upcoming years. J Korean Med Sci, 17, 611-5.
  59. Blumberg BS (2010). Primary and secondary prevention of liver cancer caused by HBV. Front Biosci (Schol Ed), 1, 756-63.

Cited by

  1. Cytotoxicity Assessments of Portulaca oleracea and Petroselinum sativum Seed Extracts on Human Hepatocellular Carcinoma Cells (HepG2) vol.15, pp.16, 2014,
  2. Talin-1 Correlates with Reduced Invasion and Migration in Human Hepatocellular Carcinoma Cells vol.15, pp.6, 2014,
  3. DEP Domain Containing 1 is a Novel Diagnostic Marker and Prognostic Predictor for Hepatocellular Carcinoma vol.15, pp.24, 2015,
  4. Portulaca oleracea Seed Oil Exerts Cytotoxic Effects on Human Liver Cancer (HepG2) and Human Lung Cancer (A-549) Cell Lines vol.16, pp.8, 2015,
  5. Epidemiology of hepatitis C virus in Iran vol.21, pp.38, 2015,
  6. Hepatocellular carcinoma in Asia: Prevention strategy and planning vol.7, pp.12, 2015,